investora2z Friday, 11/15/13 12:23:42 PM Re: None Post # of 773 The 10Q filed by the company for Q1'14 (period ending September 30, 2013) reports that the company received a revenue of $100K which relates to a milestone payment in connection with an agricultural license agreement. The loss during the period was $1.8 million or $0.78 per share compared to $2.7 million or $2.52 per share during the same period last year. The decrease in the loss per common shares was mainly due to decrease in a non-cash loss on settlement of warrant liabilities and decrease in dividends related to preferred stock. Cash & cash equivalents balance as on September 30, 2013 was $789,176, compared to $1,602,294 at the end of the previous quarter ending June 30, 2013. In addition to this, in October 2013, the Company received net proceeds of approximately $1,505,000 from the placement of common stock ($1,725,000 in gross proceeds). This has improved the cash position of the company. The Company plans to fund its future R&D / commercialization activities by using the cash presently available, by achieving milestones set forth in its current licensing agreements, by execution of new licensing agreements, and through equity and debt funding. The filing mentions that the company has sufficient cash on hand to maintain operations through March 2014. Regarding the operations, the management expressed confidence about the progress of the trials. The President of the company stated that the enrollment in cohort 3, where the dose level is significantly higher than cohort 2, is proceeding at a better pace than the previous two cohorts. While the results of cohort 3 are expected to be declared shortly, the results in the preclinical trials on mice have previously yielded encouraging results at this dose. During Q1'14, the company began treating patients at its newly opened clinical-trial site at Seattle Cancer Care Alliance.